Patent intelligence · US
US 7192932
Use of immunomodulating agents
Use of immunomodulating agents
Patent details — US 7192932
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 20, 2007
- Expiration
- Mar 15, 2027
- Applicant
- Lauras AS
- Claims
- 4
- CPC classes
- A61K, A61K31/70
Quick answer
US 7192932 (Use of immunomodulating agents) is held by Lauras AS. Status: granted. Granted Mar 20, 2007. Expires Mar 15, 2027 (1 year remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Lauras AS
- Grant date
- Expiration
- Claims
- 4
- CPC classes
- A61K, A61K31/70
More from Lauras AS
Related pharmaceutical patents in our USPTO index.
-
US 11786503
Pharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity
granted -
US 11166936
Pharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity
granted -
US 10874633
Pharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity
granted -
US 10806716
Pharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity
granted -
US 10688172
HPV particles and uses thereof
granted -
US 10596275
Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells
granted -
US 10300150
Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells
granted -
US 10179168
HPV particles and uses thereof
granted
Related coverage
BBSW AI Solution: Key Insights from the 2026 Event
The BBSW AI Solution event in Foster, USA, promises to unveil critical advancements in AI technology for the pharma industry. Stay tuned for live updates and key takeaways.
BBSW AI Solution 2026: Key Insights and Highlights
The BBSW AI Solution event in 2026 is set to unveil groundbreaking advancements in AI technology. Join us for live coverage and key insights from industry leaders.
Frequently asked questions
What is US patent 7192932?
US 7192932 (Use of immunomodulating agents) is held by Lauras AS. Status: granted. Granted Mar 20, 2007. Expires Mar 15, 2027 (1 year remaining) — relevant for patent-cliff and LOE planning.
Who owns US 7192932?
Lauras AS is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 17 pharmaceutical patents for this assignee.
When does US 7192932 expire?
Our index shows an expiration date of Mar 15, 2027 (1 year from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.